doi:10.1016/j.nrl.2021.03.003engCaronna, E.José Gallardo, V.Alpuente, A.Torres-Ferrus, M.Sánchez-Mateo, N.M.Viguera-Romero, J.López-Veloso, A.C.López-Bravo, A.Gago-Veiga, A.B.Irimia Sieira, P.Porta-Etessam, J.Santos-Lasaosa, S.Pozo-Rosich, P.Spanish, CGRP-COVID, Study, GroupSafety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications [Seguridad de los anticuerpos monoclonales anti-CGRP en pacientes con migraña durante la pandemia de COVID-19: implicaciones actuales y futuras]ART-2021-124265Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.2021http://zaguan.unizar.es/record/15130310.1016/j.nrl.2021.03.003http://zaguan.unizar.es/record/151303oai:zaguan.unizar.es:151303Neurología (Barcelona) 36 (2021), 611-617by-nc-ndhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.esinfo:eu-repo/semantics/openAccess